BR112015005227A2 - inibidores de glicosilceramida sintase - Google Patents
inibidores de glicosilceramida sintaseInfo
- Publication number
- BR112015005227A2 BR112015005227A2 BR112015005227A BR112015005227A BR112015005227A2 BR 112015005227 A2 BR112015005227 A2 BR 112015005227A2 BR 112015005227 A BR112015005227 A BR 112015005227A BR 112015005227 A BR112015005227 A BR 112015005227A BR 112015005227 A2 BR112015005227 A2 BR 112015005227A2
- Authority
- BR
- Brazil
- Prior art keywords
- synthase inhibitors
- glycosylceramide synthase
- glycosylceramide
- treatment
- inhibitors
- Prior art date
Links
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 230000002132 lysosomal effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
resumo patente de invenção: "inibidores de glicosilceramida sintase". a invenção refere-se a inibidores de glicosilceramide sintase (gcs) úteis para o tratamento de doenças metabólicas, tal como doença de depósito lisossômica, ou sozinhos ou em combinação com a terapia de substituição de enzima, doença cística e para o tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261699714P | 2012-09-11 | 2012-09-11 | |
PCT/US2013/058896 WO2014043068A1 (en) | 2012-09-11 | 2013-09-10 | Glucosylceramide synthase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015005227A2 true BR112015005227A2 (pt) | 2017-07-04 |
Family
ID=49226563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015005227A BR112015005227A2 (pt) | 2012-09-11 | 2013-09-10 | inibidores de glicosilceramida sintase |
Country Status (38)
Country | Link |
---|---|
US (3) | US20150210681A1 (pt) |
EP (2) | EP4098654A1 (pt) |
JP (1) | JP6430943B2 (pt) |
KR (1) | KR102216532B1 (pt) |
CN (3) | CN105073745B (pt) |
AR (1) | AR092522A1 (pt) |
AU (1) | AU2013315715A1 (pt) |
BR (1) | BR112015005227A2 (pt) |
CA (1) | CA2884144C (pt) |
CL (1) | CL2015000529A1 (pt) |
CR (1) | CR20150150A (pt) |
DK (1) | DK2895484T3 (pt) |
DO (1) | DOP2015000039A (pt) |
EA (2) | EA038536B1 (pt) |
ES (1) | ES2911685T3 (pt) |
GT (1) | GT201500051A (pt) |
HK (1) | HK1212681A1 (pt) |
HR (1) | HRP20220310T1 (pt) |
HU (1) | HUE058085T2 (pt) |
IL (1) | IL237355B (pt) |
JO (1) | JOP20130273B1 (pt) |
LT (1) | LT2895484T (pt) |
MA (1) | MA37975B2 (pt) |
MX (2) | MX2015003043A (pt) |
MY (1) | MY186824A (pt) |
NZ (1) | NZ706296A (pt) |
PE (1) | PE20150734A1 (pt) |
PH (1) | PH12015500431A1 (pt) |
PL (1) | PL2895484T3 (pt) |
PT (1) | PT2895484T (pt) |
RS (1) | RS63130B1 (pt) |
SG (2) | SG11201501538VA (pt) |
SI (1) | SI2895484T1 (pt) |
TN (1) | TN2015000091A1 (pt) |
TW (1) | TWI627171B (pt) |
UA (1) | UA118747C2 (pt) |
UY (1) | UY35024A (pt) |
WO (1) | WO2014043068A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
KR20150130386A (ko) * | 2013-03-15 | 2015-11-23 | 젠자임 코포레이션 | 글루코실세라마이드 신타아제 저해제의 제조 방법 |
PT3079695T (pt) * | 2013-12-11 | 2021-05-04 | Genzyme Corp | Inibidores de glicosilceramida-sintase |
FR3017867A1 (fr) * | 2014-02-21 | 2015-08-28 | Inventiva | Nouveaux composes de type phenylazetidine carboxylate ou carboxamide |
MX2017001648A (es) | 2014-08-04 | 2017-04-27 | Genzyme Corp | Biomarcadores de enfermedad poliquistica renal y usos de los mismos. |
TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
AU2016357720A1 (en) * | 2015-11-18 | 2018-07-05 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
SG10202110874TA (en) | 2016-06-07 | 2021-11-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. | Shp2阻害剤として有用な新規な複素環式誘導体 |
CN109111447A (zh) | 2017-06-23 | 2019-01-01 | 中国科学院上海药物研究所 | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 |
US20200339587A1 (en) | 2017-12-21 | 2020-10-29 | Lysosomal Therapeutics Inc. | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof |
EP3774732A4 (en) * | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN109709202A (zh) * | 2018-12-29 | 2019-05-03 | 辉源生物科技(上海)有限公司 | 一种半乳糖神经酰胺转移酶抑制剂药物的快速筛选方法 |
CA3128043A1 (en) * | 2019-02-04 | 2020-08-13 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs) |
AU2020247255A1 (en) * | 2019-03-28 | 2021-11-11 | Essa Pharma, Inc. | Androgen receptor modulators and methods for use as Proteolysis Targeting Chimera ligands |
AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
PE20220386A1 (es) | 2019-06-14 | 2022-03-18 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
JOP20210330A1 (ar) | 2019-06-14 | 2023-01-30 | Janssen Pharmaceutica Nv | مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b" |
MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
CN114007691A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 吡啶氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
JP2022538795A (ja) | 2019-06-14 | 2022-09-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラジンカルバメート及びGluN2B受容体調節因子としての使用 |
US20220289679A1 (en) | 2019-07-29 | 2022-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP4005638A4 (en) | 2019-07-29 | 2023-07-05 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
KR102483492B1 (ko) * | 2019-09-02 | 2023-01-02 | 한양대학교 에리카산학협력단 | 2,5-이치환된 피리미딘 유도체 및 이를 포함하는 약학적 조성물 |
US20220402909A1 (en) * | 2019-11-15 | 2022-12-22 | Yuhan Corporation | Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
AU2020384066A1 (en) | 2019-11-15 | 2022-04-21 | Green Cross Corporation | Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
EP4100009A1 (en) * | 2020-02-03 | 2022-12-14 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
CA3174422A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
EP4185267A1 (en) | 2020-07-24 | 2023-05-31 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
MX2023012541A (es) * | 2021-05-11 | 2023-11-03 | Yuhan Corp | Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan. |
WO2023101895A1 (en) * | 2021-11-30 | 2023-06-08 | Merck Sharp & Dohme Llc | Fused pyrazole urea analogs as glucosylceramide synthase inhibitors |
WO2023172475A2 (en) * | 2022-03-11 | 2023-09-14 | Merck Sharp & Dohme Llc | Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors |
WO2023177563A2 (en) * | 2022-03-14 | 2023-09-21 | Merck Sharp & Dohme Llc | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors |
WO2024116127A1 (en) | 2022-12-01 | 2024-06-06 | Genzyme Corporation | Venglustat in combination with a strong or moderate inhibitor of cyp3a4 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE640616A (pt) | 1962-12-19 | |||
US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4593034A (en) * | 1984-04-06 | 1986-06-03 | A. H. Robins Company, Inc. | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides |
IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
DE3878235T2 (de) * | 1988-08-04 | 1993-06-03 | Synthelabo | Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.)oct-3-yl)benzamide und thiobenzamide. |
US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
IT1228293B (it) | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
GB9106571D0 (en) | 1991-03-27 | 1991-05-15 | Erba Carlo Spa | Derivatives of substituted imidazol-2-one and process for their preparation |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
WO1995021820A1 (fr) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
WO1997017348A1 (en) | 1995-11-08 | 1997-05-15 | American Home Products Corporation | 1-azabicycloheptane derivatives and their pharmaceutical use |
SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
CA2261692A1 (en) | 1996-07-29 | 1998-02-05 | Rolf Johansson | Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation |
EP2147681A1 (en) | 1997-10-29 | 2010-01-27 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
CA2348879A1 (en) | 1998-11-02 | 2000-05-11 | Welfide Corporation | Pyrrolidine compound and pharmaceutical use thereof |
US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
KR20020084116A (ko) * | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
ATE260277T1 (de) | 2000-06-27 | 2004-03-15 | S A L V A T Lab Sa | Von arylalkylaminen abgeleitete carbamate |
WO2002016356A2 (en) * | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
WO2002015662A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
ES2275808T3 (es) * | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
JP2003267977A (ja) | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2393331T3 (es) | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
JPWO2004011430A1 (ja) | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
SE0202430D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
EP2062595A1 (en) * | 2002-12-06 | 2009-05-27 | The Feinstein Institute for Medical Research | Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
TW200529860A (en) * | 2003-12-22 | 2005-09-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
JP2007186422A (ja) | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
WO2006002375A2 (en) | 2004-06-23 | 2006-01-05 | The Feinstein Institute For Medical Research | Method of treating ileus by pharmacological activation of cholinergic receptors |
US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
US20090131470A1 (en) * | 2005-06-11 | 2009-05-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
SG165417A1 (en) * | 2005-09-23 | 2010-10-28 | Memory Pharm Corp | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
JP2009523845A (ja) * | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
BRPI0707245A2 (pt) * | 2006-01-23 | 2011-04-26 | Crystalgenomics Inc | derivados de imidazopiridina que inibem a atividade de proteìna quinase, método para a preparação destes e composição farmacêutica contendo os mesmos |
WO2007100430A2 (en) * | 2006-01-27 | 2007-09-07 | Yale University | Cytisine and acetylcholine analogs and methods of treating mood disorders |
US8367696B2 (en) * | 2007-02-09 | 2013-02-05 | Astellas Pharma Inc. | Aza-bridged-ring compound |
AU2008266960A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
US8252789B2 (en) | 2007-11-29 | 2012-08-28 | Neuraltus Pharmaceuticals, Inc. | Compositions and methods for treating lysosomal disorders |
WO2010014554A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
CN102438988B (zh) * | 2009-04-21 | 2015-06-24 | 内尔维阿诺医学科学有限公司 | 作为hsp90抑制剂的间苯二酚衍生物 |
AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
HRP20211992T1 (hr) | 2009-08-28 | 2022-04-01 | Icahn School Of Medicine At Mount Sinai | Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze |
US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
PT2685986T (pt) * | 2011-03-18 | 2020-03-05 | Genzyme Corp | Inibidor de glicosilceramida-sintase |
BR112015005400B1 (pt) | 2012-09-11 | 2022-03-08 | Hospira Australia Pty Ltd | Formulação de daptomicina liofilizada, formulação de daptomicina reconstituída, método para tratar um biofilme e método para preparar uma formulação de daptomicina liofilizada |
JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
-
2013
- 2013-09-09 JO JOP/2013/0273A patent/JOP20130273B1/ar active
- 2013-09-09 MA MA37975A patent/MA37975B2/fr unknown
- 2013-09-10 MY MYPI2015000454A patent/MY186824A/en unknown
- 2013-09-10 SG SG11201501538VA patent/SG11201501538VA/en unknown
- 2013-09-10 WO PCT/US2013/058896 patent/WO2014043068A1/en active Application Filing
- 2013-09-10 NZ NZ706296A patent/NZ706296A/en unknown
- 2013-09-10 KR KR1020157009037A patent/KR102216532B1/ko active IP Right Grant
- 2013-09-10 EA EA201590554A patent/EA038536B1/ru not_active IP Right Cessation
- 2013-09-10 MX MX2015003043A patent/MX2015003043A/es active IP Right Grant
- 2013-09-10 HR HRP20220310TT patent/HRP20220310T1/hr unknown
- 2013-09-10 PT PT137658936T patent/PT2895484T/pt unknown
- 2013-09-10 RS RS20220379A patent/RS63130B1/sr unknown
- 2013-09-10 DK DK13765893.6T patent/DK2895484T3/da active
- 2013-09-10 EP EP22154095.8A patent/EP4098654A1/en active Pending
- 2013-09-10 HU HUE13765893A patent/HUE058085T2/hu unknown
- 2013-09-10 PL PL13765893.6T patent/PL2895484T3/pl unknown
- 2013-09-10 SG SG10201701966RA patent/SG10201701966RA/en unknown
- 2013-09-10 LT LTEPPCT/US2013/058896T patent/LT2895484T/lt unknown
- 2013-09-10 EP EP13765893.6A patent/EP2895484B1/en active Active
- 2013-09-10 SI SI201331971T patent/SI2895484T1/sl unknown
- 2013-09-10 CA CA2884144A patent/CA2884144C/en active Active
- 2013-09-10 MX MX2020002867A patent/MX2020002867A/es unknown
- 2013-09-10 PE PE2015000308A patent/PE20150734A1/es unknown
- 2013-09-10 BR BR112015005227A patent/BR112015005227A2/pt not_active Application Discontinuation
- 2013-09-10 CN CN201380058586.0A patent/CN105073745B/zh active Active
- 2013-09-10 JP JP2015531307A patent/JP6430943B2/ja active Active
- 2013-09-10 EA EA202091568A patent/EA202091568A1/ru unknown
- 2013-09-10 AU AU2013315715A patent/AU2013315715A1/en not_active Abandoned
- 2013-09-10 CN CN202210106457.5A patent/CN114533729A/zh active Pending
- 2013-09-10 CN CN201810581322.8A patent/CN108864076B/zh active Active
- 2013-09-10 US US14/427,275 patent/US20150210681A1/en not_active Abandoned
- 2013-09-10 ES ES13765893T patent/ES2911685T3/es active Active
- 2013-09-11 UY UY0001035024A patent/UY35024A/es unknown
- 2013-09-11 AR ARP130103240A patent/AR092522A1/es unknown
- 2013-09-11 TW TW102132762A patent/TWI627171B/zh active
- 2013-10-09 UA UAA201503339A patent/UA118747C2/uk unknown
-
2015
- 2015-02-22 IL IL237355A patent/IL237355B/en active IP Right Grant
- 2015-02-25 DO DO2015000039A patent/DOP2015000039A/es unknown
- 2015-02-27 PH PH12015500431A patent/PH12015500431A1/en unknown
- 2015-03-02 GT GT201500051A patent/GT201500051A/es unknown
- 2015-03-04 CL CL2015000529A patent/CL2015000529A1/es unknown
- 2015-03-10 TN TNP2015000091A patent/TN2015000091A1/fr unknown
- 2015-03-19 CR CR20150150A patent/CR20150150A/es unknown
-
2016
- 2016-01-18 HK HK16100495.2A patent/HK1212681A1/zh unknown
-
2017
- 2017-04-18 US US15/490,385 patent/US11008316B2/en active Active
-
2021
- 2021-04-14 US US17/230,385 patent/US20220073508A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
BR112013023774A2 (pt) | inibidores de glicosilceramida sintase | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX2015006234A (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
BR112015022907A2 (pt) | formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila | |
SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
BR112015020667A2 (pt) | método de preparar inibidores de glucosilceramida sintase | |
MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
BR112015022308A8 (pt) | oligonucleotídeos antissenso para o tratamento de células-tronco cancerosas | |
WO2011103028A3 (en) | Compositions and methods for inhibiting mmset | |
TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
TH153719A (th) | สารยับยั้งของกลูโคซิลเซรามีดซินเทส | |
BR112013028891A2 (pt) | molécula para tratar um distúrbio inflamatório |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |